Triple Therapy Convenience by the Use of One or Multiple Inhalers and Digital Support in Chronic Obstructive Pulmonary Disease

Last updated: August 20, 2025
Sponsor: Franciscus Gasthuis
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

multi-inhaler triple therapy (Qvar + Bevespi)

single-inhaler triple therapy (Trimbow)

E-health application: Curavista app & FindAir e-device

Clinical Study ID

NCT05495698
FranciscusGasthuis
  • Ages > 40
  • All Genders

Study Summary

TRICOLON is an investigator initiated, prospective, interventional, open-label, randomized, real-world, multi-centre, 3-arms study in the Netherlands. The primary objective is to investigate in COPD patients if single-inhaler triple therapy (SITT) is superior to multi-inhaler triple therapy (MITT) in terms of adherence to inhaled corticosteroids (ICS) therapy and to investigate if SITT with e-health support is superior to MITT and SITT without e-health support.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Clinical diagnosis of COPD for at least 1 year before the screening visit

  • Aged 40 years and older

  • An indication for triple therapy according to the treating physician (following theGOLD guideline 2021(2)). Could be step-up from dual therapy or currently receivingtriple therapy (both MITT and SITT).

  • Owner of mobile device compatible with e-device app with access to internet (Androidor iOS)

  • Willing to provide written informed consent

  • Current or ex-smoker

Exclusion

Exclusion Criteria:

  • Inability to comply with study procedures or with study treatment

  • Insufficiently skilled in the Dutch language to be able to read and understand theapp. Help by third party (family members) is allowed

  • Asthma as the predominant disease according to the investigator's opinion, a pasthistory of asthma is allowed

  • Use of e-health application for COPD in the past six months

  • Patients with any other therapy that could interfere with the study drugs (accordingto the investigator's opinion)

  • Use of nebulized bronchodilators, for example via pari boy

  • Pregnant or lactating women and all women physiologically capable of becomingpregnant unless they have highly effective contraceptive

  • Patients mentally or legally incapacitated, or patients accommodated in anestablishment as a result of an official or judicial order

  • Patients without the capability to complete the questionnaires

Study Design

Total Participants: 300
Treatment Group(s): 3
Primary Treatment: multi-inhaler triple therapy (Qvar + Bevespi)
Phase:
Study Start date:
December 13, 2022
Estimated Completion Date:
December 31, 2026

Connect with a study center

  • Franciscus Gasthuis & Vlietland

    Rotterdam, Zuid-Holland 3045PM
    Netherlands

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.